Shikiar Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Shikiar Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,367	Closed	-$104K	–	94
2019 Q4	$104K	Buy	2,367 +217	+10%	+$5.55K	0.03%	92
2019 Q3	$48K	Buy	2,150 +200	+10%	+$6.38K	0.02%	87
2019 Q2	$82K	Buy	1,950 +147	+8%	+$5.08K	0.03%	86
2019 Q1	$56K	Buy	1,803 +100	+6%	+$2.66K	0.02%	83
2018 Q4	$44K	Sell	1,703 -317	-16%	-$9.25K	0.02%	73
2018 Q3	$65K	Buy	2,020 +1,353	+203%	+$49.2K	0.03%	78
2018 Q2	$23K	Buy	+667	New	+$19.6K	0.01%	83

Other funds holding SLNO

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TMC

Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Shikiar Asset Management's SLNO Position: Q1 2020 in Review

Shikiar Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2020, closing a stake of 2,367 shares — an estimated $104K sold.

Shikiar Asset Management first reported a position in SLNO in Q2 2018 and held it in 7 quarters. The position peaked at $104K in Q4 2019. 33 funds tracked by Wall St. Rank hold SLNO as of Q1 2020.

Shikiar Asset Management reported no remaining Soleno Therapeutics position as of Q1 2020 after selling out during the quarter.
Shikiar Asset Management sold 2,367 Soleno Therapeutics shares in Q1 2020, an estimated $104K.
Shikiar Asset Management first reported a position in Soleno Therapeutics in Q2 2018 and held it in 7 quarters.
Shikiar Asset Management's Soleno Therapeutics position peaked at $104K in Q4 2019.
33 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2020.

Based on Shikiar Asset Management's 13F filing for Q1 2020, filed 1 May 2020.